Asthma and COPD Drugs Market

The global Asthma and COPD Drugs Market is valued at USD 40.67 Billion in 2024 and is projected to reach a value of USD 71.7 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 5.30% between 2025 and 2035.

Key highlights of Asthma and COPD Drugs Market

• North America dominated the market in 2024, obtaining the largest revenue share of 40.1%,
• Europe region will witness remarkable growth during the forecast period,
• The Asthma segment dominated the Asthma and COPD Drugs market with the largest market share of 61.2% in 2024,
• Combination Drugs dominated the Asthma and COPD Drugs market with a significant market share in 2024,
• The growing awareness about respiratory health and early diagnosis and management drive the demand for Asthma and COPD Drugs market.

Asthma and COPD Drugs Market: Regional Overview

North America Dominated Sales with a 40.1% share in 2024. North Americas dominance in the Asthma and COPD Drugs Market is due to regions high prevalence of asthma and COPD, well-established healthcare infrastructure, robust R&D activities, and favorable reimbursement policies. For instance, in the U.S. data from the Asthma and Allergy Foundation of America reveals that nearly 26 million people have asthma, equivalent to about 1 in 13 people, with a higher prevalence among female adults. The need for efficient respiratory drugs is emphasized by this huge patient group. As a result, the sector continues to be a top priority for industry participants, encouraging ongoing innovation and investment to satisfy the rising need for drugs for COPD and asthma.

U.S. Asthma and COPD Drugs Market Overview

Asthma affects almost 21 million persons in the United States who are at least 18 years old. It is the most common chronic illness among kids. Approximately 4.8 million children under the age of 18 have asthma in the U.S. The U.S. Asthma and COPD Drugs Market presents a dynamic landscape driven by factors such as a high prevalence of respiratory diseases, robust healthcare infrastructure, and extensive research and development activities. For instance, 11.7% of adults, or 11.7 million people in the U.S. have COPD in 2022 according to the American Lung Association (ALA). The demand for effective medications remains consistently high since a maximum of the population suffers from COPD. Moreover, the countrys favorable reimbursement policies and increasing awareness about respiratory health contribute to the markets growth.

The global Asthma and COPD Drugs market can be categorized as Diseases, Medication Class, Distribution Channel, and Region.

Asthma and COPD Drugs Market: Diseases Overview

In 2024, the Asthma segment dominated the Asthma and COPD Drugs market with the significant market share, accounting for 61.2%. The Asthma and COPD Drugs market, segmented by the Diseases, includes Asthma and COPD. Asthma is a chronic condition with a high incidence of severe exacerbations, it is imperative to have treatment alternatives that are both accessible and effective. Pharmaceutical companies are investing more and more in research and development to create novel medicines, such as combination inhalers, biologics, and targeted drugs, to better treat asthma symptoms and enhance patient outcomes. Additionally, the therapeutic landscape for asthma is changing due to developments in personalized medicine and drug delivery systems, which are providing patients with more effective and customized options.

Asthma and COPD Drugs Market: Medication Class Overview

In 2024, significant revenue was generated by Asthma and COPD Drugs for Combination Drugs. The Medication Class segment is bifurcated into Combination Drugs, Bronchodilators, Inhaled Corticosteroids (ICS), Short Acting Beta Agonists (SABA), Long-Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA), Anticholinergics, Anti-Inflammatories, Others. Combination drugs provide greater treatment effects and better patient outcomes because they can target distinct areas of asthma and COPD with numerous active components necessary for these long-term respiratory diseases. The market for combination drugs is anticipated to increase steadily as long as pharmaceutical companies keep funding the creation and marketing of novel combination medicines. This growth will be fueled by patients' constant need for more convenient and efficient treatment alternatives for COPD and asthma.

Key Trends

• There is a growing trend towards sustained innovation in medication delivery systems, such the creation of digital health technology and smart inhalers which helps to improves patient adherence, treatment effectiveness, and disease management.
• There are advancements in pharmacogenomics and biomarker identification to customized treatment plans catered to the unique characteristics of each patient, maximizing the choice and dosage of medications for improved results.
• There is a shift towards combination treatments that address several pathophysiology of COPD and asthma so many pharmaceutical firms are developing such innovative drugs. These treatments are more convenient and more effective than monotherapy.

Premium Insights

The increasing prevalence of respiratory diseases globally is driven by factors such as rising air pollution levels due to industrialization, urbanization, and lifestyle changes. Technological advancements in the drug delivery systems and the development of novel therapies, including biologics targeting specific inflammatory pathways, are enhancing treatment efficacy and patient outcomes. For instance, Globally, chronic obstructive pulmonary disease, or COPD, is the third most common cause of mortality. In high-income nations, tobacco use is the primary cause of COPD cases, more than 70%. 30 to 40 percent of COPD cases in LMICs are caused by tobacco use, and one important risk factor is indoor air pollution. Furthermore, the global market for asthma and COPD medications is expanding due to the growing number of elderly people. For instance, the elderly population will rise to 1.5 billion by 2050. The percentage of adults 65 and older increased dramatically worldwide, rising to 16% in 2050. Additionally, favorable reimbursement policies and growing healthcare expenditure facilitate patient access to essential treatments, further fueling market growth.

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

The rising incidence of asthma and COPD globally is a significant driver for the market, primarily fueled by several interconnected factors

Risk factors like smoking remains one of the leading causes of these respiratory diseases. Numerous dangerous compounds included in tobacco can harm the lungs and cause long-term illnesses including COPD and asthma. More people moving to cities exposes them to higher levels of air pollution, which can worsen respiratory conditions that already exist and increase the risk of developing COPD and asthma. This problem is exacerbated by indoor pollution, vehicle emissions, and industrial activity, all of which create conditions that are favorable for respiratory illnesses.

Key players face difficulties due to strict regulatory standards for drug approval and growing regulatory agency scrutiny

Developing new drugs for asthma and COPD requires clinical trials to demonstrate efficacy and safety, which can be time-consuming and costly. Strict regulations are enforced by regulatory bodies like the FDA in the US and the EMA in Europe to guarantee the efficacy, safety, and quality of pharmaceutical products. Market dynamics are impacted by the complexity, lengthening of timetables, and increased firm expenses associated with complying with these rules during the drug development process.

Advancements in pharmacogenomics and biomarker identification present opportunities for personalized treatment approaches in asthma and COPD

Pharmacogenomics involves studying how an individuals genetic makeup influences their response to drugs, allowing for tailored treatment regimens based on genetic factors. Identifying specific molecules or indications in a patients body that can be used to forecast the course of their disease or determine whether a medication will work is known as biomarker identification. Healthcare professionals enhance therapy selection and dosage by utilizing these advancements, which will enhance treatment results and patient satisfaction. In the long run, personalized medicine may drive favorable market dynamics by increasing the efficacy of COPD and asthma medicines while reducing side effects.

Competitive Landscape

The competitive landscape of the Asthma and COPD Drugs market is characterized by the presence of key pharmaceutical players such as Pfizer Inc., Teva Pharmaceutical Industries Ltd, Merck & Co. Inc among others dominated the industry with their extensive portfolios of inhalers and respiratory medications. Additionally, emerging biopharmaceutical firms are entering the fray, leveraging innovative therapies and advanced technologies to challenge traditional market leaders. Regulatory approvals, pricing strategies, and investment in research and development are pivotal factors influencing competitiveness within this dynamic market, as companies strive to address the unmet needs of patients and capitalize on the growing prevalence of respiratory diseases globally.

The key players in the global Asthma and COPD Drugs market include - Novartis AG (Switzerland) among others.

Recent Market Developments

• In 2024, The FDA accepted Dupixent®s supplemental Biologics License Application for Priority Review, considering it an add-on maintenance treatment for certain adults with uncontrolled COPD. The FDAs decision is expected by June 27, 2024. Similar submissions are under review in China and the European Union.
• In 2023, Verona Pharma plc (Nasdaq: VRNA) announced FDA approval for their New Drug Application (NDA) for ensifentrine maintenance treatment for COPD patients. The FDA has set a target action date of June 26, 2024, and does not plan an advisory committee meeting for the application.
• In 2024, AstraZeneca initiates a Phase III trial to assess BREZTRI AEROSPHERE®s impact on severe cardiopulmonary outcomes in COPD patients with elevated risk, regardless of exacerbation history.
• In 2024, GSK announces a monthly out-of-pocket cost cap of $35 for eligible patients using its asthma and COPD inhalers in the U.S.U.S., aiming to improve access to respiratory medicines for those with financial constraints.
• In 2022, Verona announced encouraging results from the phase 3 ENHANCE-2 clinical trial, which treats chronic obstructive pulmonary disease (COPD) with ensifentrine. One molecule with both bronchodilator and anti-inflammatory properties is ensifentrine, a potential product.
• In 2022, Glenmark introduced a unique fixed-dose combination (FDC) medication for Indian patients with very severe asthma called Indacaterol + Mometasone. The FDC was marketed under the trade name Indamet.